Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (7): 416-419.
Previous Articles Next Articles
JU Mengqi1,2, YUAN Lijia3, LV Xufeng3, YANG Lina1,2, YANG Yue1,2,*
Received:
2019-08-06
Revised:
2019-08-06
Online:
2019-07-20
Published:
2019-08-06
CLC Number:
JU Mengqi, YUAN Lijia, LV Xufeng, YANG Lina, YANG Yue. Enlightenment of Market Share Liability on Compensation System for Delayed Drug Injury in China[J]. Chinese Journal of Pharmacovigilance, 2019, 16(7): 416-419.
[1] Meyer J, Palewski S.DES: The Timebomb Drug[J]. Ajn the American Journal of Nursing, 1985, 85(3):336. [2] Kaufman R H, Adam E, Hatch E E, et al.Continued Follow-up of Pregnancy Outcomes in Diethylstilbestrol- exposed Offspring[J]. Obstetrics & Gynecology, 2000, 96(4):483-489. [3] Bernstein A.Formed by thalidomide: mass torts as a false cure for toxic exposure[J].Columbia Law Rev,1997, 97(7):2153-2176. [4] Wagner M J, Peterson L L.The new Restatement (Third) of Torts-shelter from the product liability storm for phar- maceutical companies and medical device manufacturers?[J]. Food & Drug Law Journal, 1998, 53(2):225-242. [5] 马新彦,孙大伟. 我国未来侵权法市场份额规则的立法证成-以美国侵权法研究为路径而展开[J]. 吉林大学社会科学学报, 2009, 49(1):93-101. [6] Walker V. R.Uncertainties in tort liability for uncertainty[J]. Law, Probability and Risk, 2002, 1(2):175-184. [7] 史尊魁. 引入美国市场份额规则的思考[J]. 华南理工大学学报(社会科学版), 2010, 12(5):93-98. [8] M. Stuart Madden, Jamie Holian. Defendant Indeterminacy: New Wine into Old Skins[J]. LA Law Rev 2007, 67(3):785-822. [9] 王凌俊. 美国市场份额责任的判例厘清与规则借鉴[D].上海: 华东政法大学, 2011. [10] 刘青. 市场份额责任的基础理论研究[D]. 苏州:苏州大学, 2012. [11] 靳昕. 市场份额责任在我国的适用[D].北京:中国政法大学,2011. |
[1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
[2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
[3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
[4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
[6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
[7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
[8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
[9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
[10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
[11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
[12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
[13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
[14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
[15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||